国际医学(000516) - 2025 Q2 - 季度业绩预告

Xi'an International Medical Investment Co., Ltd. 2025 Semi-Annual Performance Forecast This report provides Xi'an International Medical Investment Co., Ltd.'s semi-annual performance forecast for 2025, detailing expected losses and revenue changes Key Performance Forecast Data The company projects a net loss for H1 2025, with revenue significantly decreasing year-over-year and net loss after non-recurring items expected to widen 2025 Semi-Annual Performance Forecast | Item | Current Reporting Period (Jan 1 - Jun 30, 2025) | Prior Year Period | | :--- | :--- | :--- | | Net Profit Attributable to Shareholders of Listed Company | Loss: CNY 160.00 million – CNY 170.00 million | Loss: CNY 173.61 million | | Net Profit After Non-Recurring Items | Loss: CNY 182.00 million – CNY 192.00 million | Loss: CNY 138.90 million | | Basic Earnings Per Share | Loss: CNY 0.0715/share – CNY 0.0760/share | Loss: CNY 0.0768/share | | Operating Revenue | CNY 2.01 billion – CNY 2.05 billion | CNY 2.42 billion | Analysis of Performance Changes The company attributes its H1 2025 loss and revenue decline to external policy impacts and insufficient revenue to cover operational costs and expenses - During the reporting period, the company's operating revenue decreased year-over-year, primarily due to industry dynamic adjustments such as market fluctuations, centralized procurement (volume-based purchasing), and DRG (diagnosis-related group) payment policy reforms[3][4] - Despite the company's efforts to adjust its business structure and implement cost reduction and efficiency improvements, the total operating revenue has not yet covered operating costs and period expenses, which is the direct cause of the loss[4] Risk Warning and Statement The company clarifies that the performance forecast is a preliminary, unaudited estimate, advising investors to await the official semi-annual report for final data and to be aware of investment risks - The financial data in this performance forecast are preliminary estimates by the company's finance department and have not been audited by a certified public accountant[2][5] - The company advises investors that specific financial data will be detailed in the 2025 semi-annual report, urging investors to be aware of investment risks[5]